Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

10.1186/s13148-016-0245-y

Saved in:

Bibliographic Details
Main Authors:	Pera, B, Tang, T, Marullo, R, Yang, S.-N, Ahn, H, Patel, J, Elstrom, R, Ruan, J, Furman, R, Leonard, J, Cerchietti, L, Martin, P
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	2020
Subjects:	azacitidine bendamustine bortezomib brentuximab vedotin carboplatin carmustine chlormethine cisplatin cyclophosphamide cytarabine decitabine dexamethasone DNA methyltransferase inhibitor doxorubicin etoposide fluorodeoxyglucose f 18 histone deacetylase inhibitor ifosfamide melphalan methylprednisolone prednisolone prednisone procarbazine protein p21 rituximab veltuzumab vincristine vorinostat antineoplastic agent hydroxamic acid adult aged anemia animal experiment animal model antineoplastic activity Article autologous stem cell transplantation B cell lymphoma cancer mortality cancer radiotherapy cancer recurrence chemosensitization clinical article computer assisted emission tomography controlled study diarrhea disease model drug dose comparison drug potentiation drug safety drug tolerability epigenetics fatigue female fever gastrointestinal disease gene therapy hematologic disease human human cell hyperamylasemia hyperbilirubinemia hyperglycemia hypoglycemia in vitro study in vivo study kidney dysfunction large cell lymphoma leukopenia male metabolic disorder mouse multiple cycle treatment nausea neutropenia nonhuman overall survival phase 1 clinical trial priority journal thrombocytopenia thromboembolism treatment outcome treatment response very elderly vomiting analogs and derivatives clinical trial DNA methylation drug effects genetic epigenesis Lymphoma, Large B-Cell, Diffuse middle aged tumor cell line Adult Aged Aged, 80 and over Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Azacitidine Cell Line, Tumor DNA Methylation Epigenesis, Genetic Female Histone Deacetylase Inhibitors Humans Hydroxamic Acids Male Middle Aged Treatment Outcome
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/179920
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-179920
record_format	dspace
spelling	sg-nus-scholar.10635-1799202023-11-01T07:54:51Z Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients Pera, B Tang, T Marullo, R Yang, S.-N Ahn, H Patel, J Elstrom, R Ruan, J Furman, R Leonard, J Cerchietti, L Martin, P DUKE-NUS MEDICAL SCHOOL azacitidine bendamustine bortezomib brentuximab vedotin carboplatin carmustine chlormethine cisplatin cyclophosphamide cytarabine decitabine dexamethasone DNA methyltransferase inhibitor doxorubicin etoposide fluorodeoxyglucose f 18 histone deacetylase inhibitor ifosfamide melphalan methylprednisolone prednisolone prednisone procarbazine protein p21 rituximab veltuzumab vincristine vorinostat antineoplastic agent azacitidine decitabine histone deacetylase inhibitor hydroxamic acid vorinostat adult aged anemia animal experiment animal model antineoplastic activity Article autologous stem cell transplantation B cell lymphoma cancer mortality cancer radiotherapy cancer recurrence chemosensitization clinical article computer assisted emission tomography controlled study diarrhea disease model drug dose comparison drug potentiation drug safety drug tolerability epigenetics fatigue female fever gastrointestinal disease gene therapy hematologic disease human human cell hyperamylasemia hyperbilirubinemia hyperglycemia hypoglycemia in vitro study in vivo study kidney dysfunction large cell lymphoma leukopenia male metabolic disorder mouse multiple cycle treatment nausea neutropenia nonhuman overall survival phase 1 clinical trial priority journal thrombocytopenia thromboembolism treatment outcome treatment response very elderly vomiting analogs and derivatives clinical trial DNA methylation drug effects genetic epigenesis Lymphoma, Large B-Cell, Diffuse middle aged tumor cell line Adult Aged Aged, 80 and over Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Azacitidine Cell Line, Tumor DNA Methylation Epigenesis, Genetic Female Histone Deacetylase Inhibitors Humans Hydroxamic Acids Lymphoma, Large B-Cell, Diffuse Male Middle Aged Treatment Outcome 10.1186/s13148-016-0245-y Clinical Epigenetics 8 1 79 2020-10-26T05:06:32Z 2020-10-26T05:06:32Z 2016 Article Pera, B, Tang, T, Marullo, R, Yang, S.-N, Ahn, H, Patel, J, Elstrom, R, Ruan, J, Furman, R, Leonard, J, Cerchietti, L, Martin, P (2016). Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clinical Epigenetics 8 (1) : 79. ScholarBank@NUS Repository. https://doi.org/10.1186/s13148-016-0245-y 18687075 https://scholarbank.nus.edu.sg/handle/10635/179920 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	azacitidine bendamustine bortezomib brentuximab vedotin carboplatin carmustine chlormethine cisplatin cyclophosphamide cytarabine decitabine dexamethasone DNA methyltransferase inhibitor doxorubicin etoposide fluorodeoxyglucose f 18 histone deacetylase inhibitor ifosfamide melphalan methylprednisolone prednisolone prednisone procarbazine protein p21 rituximab veltuzumab vincristine vorinostat antineoplastic agent azacitidine decitabine histone deacetylase inhibitor hydroxamic acid vorinostat adult aged anemia animal experiment animal model antineoplastic activity Article autologous stem cell transplantation B cell lymphoma cancer mortality cancer radiotherapy cancer recurrence chemosensitization clinical article computer assisted emission tomography controlled study diarrhea disease model drug dose comparison drug potentiation drug safety drug tolerability epigenetics fatigue female fever gastrointestinal disease gene therapy hematologic disease human human cell hyperamylasemia hyperbilirubinemia hyperglycemia hypoglycemia in vitro study in vivo study kidney dysfunction large cell lymphoma leukopenia male metabolic disorder mouse multiple cycle treatment nausea neutropenia nonhuman overall survival phase 1 clinical trial priority journal thrombocytopenia thromboembolism treatment outcome treatment response very elderly vomiting analogs and derivatives clinical trial DNA methylation drug effects genetic epigenesis Lymphoma, Large B-Cell, Diffuse middle aged tumor cell line Adult Aged Aged, 80 and over Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Azacitidine Cell Line, Tumor DNA Methylation Epigenesis, Genetic Female Histone Deacetylase Inhibitors Humans Hydroxamic Acids Lymphoma, Large B-Cell, Diffuse Male Middle Aged Treatment Outcome
spellingShingle	azacitidine bendamustine bortezomib brentuximab vedotin carboplatin carmustine chlormethine cisplatin cyclophosphamide cytarabine decitabine dexamethasone DNA methyltransferase inhibitor doxorubicin etoposide fluorodeoxyglucose f 18 histone deacetylase inhibitor ifosfamide melphalan methylprednisolone prednisolone prednisone procarbazine protein p21 rituximab veltuzumab vincristine vorinostat antineoplastic agent azacitidine decitabine histone deacetylase inhibitor hydroxamic acid vorinostat adult aged anemia animal experiment animal model antineoplastic activity Article autologous stem cell transplantation B cell lymphoma cancer mortality cancer radiotherapy cancer recurrence chemosensitization clinical article computer assisted emission tomography controlled study diarrhea disease model drug dose comparison drug potentiation drug safety drug tolerability epigenetics fatigue female fever gastrointestinal disease gene therapy hematologic disease human human cell hyperamylasemia hyperbilirubinemia hyperglycemia hypoglycemia in vitro study in vivo study kidney dysfunction large cell lymphoma leukopenia male metabolic disorder mouse multiple cycle treatment nausea neutropenia nonhuman overall survival phase 1 clinical trial priority journal thrombocytopenia thromboembolism treatment outcome treatment response very elderly vomiting analogs and derivatives clinical trial DNA methylation drug effects genetic epigenesis Lymphoma, Large B-Cell, Diffuse middle aged tumor cell line Adult Aged Aged, 80 and over Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Azacitidine Cell Line, Tumor DNA Methylation Epigenesis, Genetic Female Histone Deacetylase Inhibitors Humans Hydroxamic Acids Lymphoma, Large B-Cell, Diffuse Male Middle Aged Treatment Outcome Pera, B Tang, T Marullo, R Yang, S.-N Ahn, H Patel, J Elstrom, R Ruan, J Furman, R Leonard, J Cerchietti, L Martin, P Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients
description	10.1186/s13148-016-0245-y
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Pera, B Tang, T Marullo, R Yang, S.-N Ahn, H Patel, J Elstrom, R Ruan, J Furman, R Leonard, J Cerchietti, L Martin, P
format	Article
author	Pera, B Tang, T Marullo, R Yang, S.-N Ahn, H Patel, J Elstrom, R Ruan, J Furman, R Leonard, J Cerchietti, L Martin, P
author_sort	Pera, B
title	Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients
title_short	Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients
title_full	Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients
title_fullStr	Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients
title_full_unstemmed	Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients
title_sort	combinatorial epigenetic therapy in diffuse large b cell lymphoma pre-clinical models and patients
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/179920
_version_	1781792346880344064

Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

Similar Items